From ASHP
- Considerations for Prioritizing Medications for Mechanically Ventilated Patients in Intensive Care Units [PDF]
- Ordering and Administering COVID-19 Therapeutics: Casirivimab and Imdevimab (Free CPE)
- AMA, APhA, ASHP Call for Immediate End to Prescribing, Dispensing, and Use of Ivermectin to Prevent or Treat COVID-19 Outside Clinical Trials
- AMA-APhA-ASHP Joint Statement on Ensuring Access to Medications Used to Treat COVID-19 [PDF]
- ASHP-ASA Joint Statement on Minimizing Medication Waste During COVID-19 Pandemic [PDF]
- Q&A from Midyear 2020 Session: COVID-19 - Care of the Critically Ill Patient: A Focus on the Management of Acute Respiratory Distress Syndrome and Coagulopathy [PDF]
Outpatient Therapies Authorized for Treatment or Prevention of COVID-19
- Side-by-Side Overview of Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19 (HHS ASPR)
- COVID-19 Therapeutics (HHS ASPR)
- COVID-19 Therapeutics Expiration Date Extensions
- Outpatient COVID-19 Therapeutic Decision Guide (HHS ASPR) [PDF]
- COVID-19 Monoclonal Antibody Communications Toolkit (HHS ASPR)
- Federal Response to COVID-19: Monoclonal Antibody Playbook [PDF]
- COVID-19 Therapeutic Updates (HHS ASPR)
- Health Partner Ordering Portal FAQ (HSS ASPR)
- Expanding Access to COVID-19 Therapeutics (PREP Act 9th Amendment) (HHS ASPR)
- COVID-19 Outpatient Treatment Locator (HHS)
- COVID-19 Resources for Healthcare Professionals
- NIH Treatment Guidelines: Anti-SARS-CoV-2 Monoclonal Antibodies
- NIH Treatment Guidelines: Prevention of SARS-CoV-2 Infection
- Updated Statement on the Prioritization of Anti-SARS-CoV-2 mAbs (NIH)
- NIH Guidelines Statement on Therapies for High-Risk Nonhospitalized Patients with Mild to Moderate COVID-19
- CMS Reimbursement Rates for mAb Administration (CMS)
- Monoclonal Antibody COVID-19 Infusion (CMS)
- COVID-19 Monoclonal Antibody Therapeutics Calculator for Infusion Sites (HHS)
- Paxlovid (nirmatrelvir/ritonavir)
- FDA Letter of Authorization [PDF]
- FDA Fact Sheet for Healthcare Providers - Paxlovid EUA [PDF]
- Dear Healthcare Provider Letter (Paxlovid)
- FAQs on Paxlovid EUA (FDA) [PDF]
- NIH Statement on Paxlovid Drug-Drug Interactions (NIH)
- Medication Safety Issues With Newly Authorized Paxlovid (ISMP)
- PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers
- Paxlovid Information Sheet (HHS ASPR)
- Lagevrio (molnupiravir)
- FDA Letter of Authorization [PDF]
- FDA Fact Sheet for Healthcare Providers-Molnupiravir EUA [PDF]
- FAQs on Molnupiravir EUA (FDA) [PDF]
- Lagevrio Information Sheet (HHS ASPR)
- Bebtelovimab
- Sotrovimab
- FDA Letter of Authorization [PDF]
- FDA Fact Sheet for Healthcare Providers-Sotrovimab EUA [PDF]
- FAQs on Sotrovimab EUA (FDA) [PDF]
- Bamlanivimab and Etesevimab
- REGEN-COV (casirivimab and imdevimab)
- Evusheld (tixagevimab/cilgavimab)
- Remdesivir
Other Treatment and Supportive Care Resources
- Kineret (anakinra)
- COVID-19 Test to Treat Initiative (HHS ASPR)
- FDA Fact Sheet for Health Care Providers EUA of Veklury (remdesivir) for Hospitalized Pediatric Patients
- FDA Fact Sheet for Health Care Providers EUA of Baricitinib for COVID-19
- FDA Fact Sheet for Healthcare Providers EUA of Tocilizumab
- BARDA COVID-19 Medical Countermeasure Portfolio
- Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates with Suspected or Confirmed COVID-19 (From AHA, AAP, AARC, ACEP, SCCA, ASA, AACCN)
- Google's COVID-19 Research Explorer
- NIH COVID-19 Treatment Guidelines
- COVID-19 Real-Time Learning Network (IDSA)
- IDSA Guidelines on the Treatment and Management of Patients With COVID-19
- COVID-19 Claims Reimbursement to Healthcare Providers and Facilities for the Uninsured (HRSA)
- Sanford Guide: SARS-CoV-2 and COVID-19 Material
- ClinicalTrials.gov (for COVID-19)